Paul Tudor Jones Pharvaris N.V. Transaction History
Tudor Investment Corp Et Al
- $21.5 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding PHVS
# of Institutions
81Shares Held
51MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY8.03MShares$189 Million7.09% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.78MShares$113 Million76.4% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.64MShares$109 Million78.75% of portfolio
-
Viking Global Investors LP3.65MShares$86 Million0.26% of portfolio
-
Eqt Fund Management S.A R.L.3.42MShares$80.6 Million4.59% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $795M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...